Milestone Pharmaceuticals Inc. (MIST) – What Are Analysts Thinking About This Stock?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $6.40.

A number of brokerages recently issued reports on MIST. HC Wainwright reissued a “buy” rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. Cantor Fitzgerald initiated coverage on Milestone Pharmaceuticals in a research report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, October 12th. Finally, Zacks Research raised Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th.

Milestone Pharmaceuticals Stock Performance

NASDAQ MIST opened at $0.70 on Friday. Milestone Pharmaceuticals has a 52 week low of $0.69 and a 52 week high of $3.06. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13. The company has a 50-day moving average price of $0.94 and a two-hundred day moving average price of $1.27.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.82 million. Sell-side analysts expect that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. RVW Wealth LLC bought a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at about $994,000. Guardian Wealth Advisors LLC NC lifted its holdings in Milestone Pharmaceuticals by 21.1% in the second quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock worth $455,000 after purchasing an additional 59,200 shares during the period. Seven Fleet Capital Management LP acquired a new stake in Milestone Pharmaceuticals in the first quarter worth about $397,000. TRU Independence Asset Management 2 LLC acquired a new stake in Milestone Pharmaceuticals in the second quarter worth about $201,000. Finally, Valeo Financial Advisors LLC grew its position in Milestone Pharmaceuticals by 12.2% in the 3rd quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock valued at $127,000 after buying an additional 16,000 shares in the last quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s lead product candidate is etripamil, a short-acting calcium channel blocker formulated as a nasal spray and designed for rapid, patient-administered treatment.

Etripamil has been studied primarily for paroxysmal supraventricular tachycardia (PSVT), a condition characterized by episodes of abnormally rapid heart rate. The product is intended to provide patients with an option for treating episodes outside of a hospital or clinic, potentially reducing the need for emergency medical intervention.